Procter & Gamble (PG) Form 144 Filed for 10,686-Share Sale via Morgan Stanley
Rhea-AI Filing Summary
Procter & Gamble Company (PG) Form 144 notice: The filer notified intent to sell 10,686 shares of Procter & Gamble common stock through Morgan Stanley Smith Barney on 08/19/2025 on the NYSE. The filing lists an aggregate market value of $1,655,314.83 and reports 2,342,371,488 shares outstanding. The shares to be sold were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company; the acquisition quantity is reported as 22,496 shares with payment on 08/18/2025. The filer attests there is no undisclosed material adverse information and includes the standard signature and criminal-penalty notice applicable to Form 144.
Positive
- Compliance disclosure: The filer submitted a Form 144 with broker, share amount, aggregate market value, and sale date as required.
- Transaction detail: Acquisition method and date (Performance Stock Program Award on 08/18/2025) are explicitly stated.
- Broker and market identified: Morgan Stanley Smith Barney and NYSE are named for the proposed sale.
Negative
- None.
Insights
TL;DR: Routine Rule 144 sale notice disclosing a small issuance and planned sale with full transaction details.
The filing is a standard Form 144 reporting a proposed resale of 10,686 Procter & Gamble shares through Morgan Stanley Smith Barney with an aggregate value of $1,655,314.83. It specifies the shares were acquired the prior day via a Performance Stock Program Award (22,496 shares acquired 08/18/2025). The notice also confirms no securities of the issuer were sold by the reporting person in the past three months. For investors, this document simply documents compliance with Rule 144 resale requirements and provides quantity, price aggregate, broker, and acquisition details.
TL;DR: Filing meets disclosure obligations; includes standard attestation on material information.
The Form 144 provides the necessary procedural disclosures: class of security, broker identification, number of shares to be sold, aggregate market value, acquisition date and nature (Performance Stock Program Award), and the issuer share count. The signer makes the required representation that no undisclosed material adverse information exists. There are no reported sales in the prior three months. From a governance perspective, this filing appears complete for a Rule 144 transaction.